Clinical Trials Logo

Clinical Trial Summary

1. To examine structural brain changes in patients with depression measured using voxel based morphometry(VBM) in comparison with healthy subjects. 2. Relation between grey mater volume (GMV) and other structural changes, and the severity of clinical symptoms. 3. To study if there is structural brain difference between psychotic and non-psychotic depression


Clinical Trial Description

Depression is a major psychiatric disorder and a leading cause of disability worldwide. The clinical representation encompasses affective, cognitive and somatic complains such as low mood, anxiety, lack of pleasure and interest, disturbances of sleep and appetite, decreased self-esteem, thoughts of guilt, hopelessness, and even suicide. Major depressive disorder (MDD) with psychotic features (psychotic depression) is a severe disorder with a lifetime prevalence of 0.35-1% . Over the last decades, increasing evidence from post-mortem studies and in vivo studies emerged that mood disorder can induce structural and morphometric changes of the brain The development of magnetic resonance imaging (MRI) has allowed for more advanced structural imaging Several structural magnetic resonance imaging (s MRI) studies have identified key brain areas involved in MDD. In particular, voxel-based morphometry (VBM), it is helpful in quantitatively identifying unexpected anatomic changes studies have found that MDD is associated with widespread local brain abnormalities, mainly affecting the frontal gyrus, insula, temporal lobes and anterior cingulate gyrus . Structural white matter alterations have also been reported within the inferior parietal lobule and frontal gyrus . Many studies are positive about grey matter (GM) volume reductions in various cortical regions in depressed patients compared to healthy controls . The most consistent findings appear to be related to GM loss in medial frontal cortex (MFC), anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC) with less evidence about subcortical structures such as the amygdala and the hippocampus . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05034523
Study type Observational
Source Assiut University
Contact Doaa Elhefny, MSC
Phone +201022388263
Email [email protected]
Status Not yet recruiting
Phase
Start date September 1, 2021
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT00751504 - Quetiapine in the Treatment of Psychotic Depression - a Pilot Study Phase 3
Active, not recruiting NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Completed NCT01427608 - Sustaining Remission of Psychotic Depression Phase 4
Terminated NCT00637494 - A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features Phase 3
Completed NCT00556140 - The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression Phase 3
Completed NCT00400166 - Recovery Guide Intervention for Recurrent Psychiatric Hospitalization N/A